Richard Ferraro, MD

DocwireNews

Editor&rsquo;s Note:&nbsp; Richard A. Ferraro, MD, is a cardiology fellow at the Johns Hopkins Heart and Vascular Institute. He is also a guest <a href="https://www.cardionerds.com/correspondents/">correspondent</a> for the CardioNerds, a DocWire News content partner, and the producer of the CardioNerds podcast. Read more from the CardioNerds <a href="https://www.docwirenews.com/cardio-nerds/">here</a>. Follow Dr. Ferraro on Twitter <a href="https://twitter.com/RichardAFerraro">@RichardAFerraro</a>.&nbsp;<a href="https://www.docwirenews.com/docwire-pick/cardiology-picks/coronary-artery-calcium-active-mortality/">Coronary artery calcium</a> (CAC) and biomarkers have been of interest in recent years as predictors of downstream cardiovascular events. While both certainly hold important roles, which of the two is a better predictor? At the <a href="https://www.aspconline.org/2021virtualsummit/">American Society for Preventive Cardiology (ASPC)</a>, two giants of their respective fields took to the virtual stage to debate just this question.The debate itself was moderated by ASPC board member Dr. Ann Marie Navar from the University of Texas &ndash; Southwestern. In defense of coronary artery calcium was Dr. Khurram Nasir from Houston Methodist Hospital, Chief of the Division of Cardiovascular Prevention and Wellness.&nbsp; Speaking for biomarkers was Dr. Christie Ballantyne of the Baylor College of Medicine, Chief of Cardiology and Cardiovascular Research.Dr. Nasir began with an important discussion on risk stratification.&nbsp; In terms of atherosclerotic risk, &ldquo;calcium score has been established as the front-runner as there is no better marker that I know predicts those who are at the highest risk among those without established cardiovascular disease.&rdquo; Conversely, Dr. Nasir also noted that calcium scoring may &ldquo;de-risk&rdquo; some patients, thus allowing for better overall prognostication. He did acknowledge, however, that CAC zero does not equate to zero risk. Dr. Nasir concluded pointedly, questioning if it was the time to leave behind the dogma of legacy tools and embrace technology and the big data tools of the future to best risk stratify.Dr. Ballantyne remarked that our goal should not just be the prevention of atherosclerosis, but accompanying comorbidities such as diabetes and heart failure. This is where biomarkers come in. He presented a case to illustrate &ndash; a young patient with hypertension, elevated LDL, and a high Lp(a) may have a<a href="https://www.docwirenews.com/docwire-pick/cardiology-picks/cac-scoring-associated-with-accurate-classification-of-patients-at-risk-of-ascvd-who-might-benefit-from-statins/"> CAC score</a> of zero and yet be at tremendous lifetime risk. He further noted that the most common event after visit 5 of the longitudinal ARIC study was not an atherosclerotic event, but heart failure, an outcome not predicted by CAC alone. He concluded by stating that while CAC is a useful tool for atherosclerotic disease risk, it does not have the predictive value required for the development and prevention of related disease states. Biomarkers, therefore, are the superior instrument in this regard.Does CAC or biomarkers win the day as the better prognostic tool in cardiovascular prevention? Where do you side in the debate?<blockquote class="twitter-tweet" data-width="500" data-dnt="true">
1/ Ready for a <a href="https://twitter.com/hashtag/Tweetorial?src=hash&amp;ref_src=twsrc%5Etfw">#Tweetorial</a> on coronary artery calcium (CAC) score? 
Keep reading to: &#9762;&#65039;Understand the pathophysiology of coronary artery calcium &#9762; Identify the utility of the CAC score &#9762;&#65039;Recognize the limitations of CAC scoring <a href="https://t.co/f9wAPFe904">pic.twitter.com/f9wAPFe904</a>
&mdash; Gurleen Kaur, MD (@Gurleen_Kaur96) <a href="https://twitter.com/Gurleen_Kaur96/status/1393340253172273157?ref_src=twsrc%5Etfw">May 14, 2021</a>
</blockquote><script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script><blockquote class="twitter-tweet" data-width="500" data-dnt="true">
<a href="https://twitter.com/hashtag/Perspective?src=hash&amp;ref_src=twsrc%5Etfw">#Perspective</a>: Zero Coronary Artery Calcium Score &ndash; Desirable, but Enough? <a href="https://twitter.com/hashtag/AHAJournals?src=hash&amp;ref_src=twsrc%5Etfw">#AHAJournals</a> <a href="https://twitter.com/CBallantyneMD?ref_src=twsrc%5Etfw">@CBallantyneMD</a> <a href="https://twitter.com/vijay_nambi?ref_src=twsrc%5Etfw">@vijay_nambi</a> <a href="https://t.co/tA1jXwOmHs">https://t.co/tA1jXwOmHs</a>
&mdash; Circulation (@CircAHA) <a href="https://twitter.com/CircAHA/status/1303396695364055041?ref_src=twsrc%5Etfw">September 8, 2020</a>
</blockquote><script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script>&nbsp;

Eric Bergson, MD

Rob Dillard

The Role of Multidisciplinary Care in Head and Neck Cancer

Head and Neck Cancer

Sara Nunnery, MD, MSCI

Trastuzumab Deruxtecan in HER2-Low Breast Cancer: Who’s the Right Patient?

HER2 Breast Cancer

Meghan Sise, MD

Joel M. Topf, MD, FACP

Redefining Carboplatin Dosing

NKF Spring Clinical Meetings 2025

Latest News

Coronary Artery Calcium versus Biomarkers: Which Better Predicts Cardiovascular Events?

Cardionerds is an entertaining and educational medical cardiology podcast created by three cardiologists. They want to bring high yield cardiovascular concepts in a fun and engaging format for their listeners of all levels. Click below to learn more!

CardioNerds

Editor's Note:  Richard A. Ferraro, MD, is a cardiology fellow at the Johns Hopkins Heart and Vascular Institute. He is also a guest correspondent for the CardioNerds, a ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HR Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe